What is Heartflow's latest dividend and current dividend yield?

What guidance did Heartflow's management provide for the next earnings period?

What were the key takeaways from Heartflow's earnings call?

What does Heartflow do and what are its main business segments?

Did Heartflow beat or miss consensus estimates last quarter?

What is the market's earnings forecast for Heartflow next quarter?

What were the key takeaways from Heartflow’s earnings call?

What factors drove the changes in Heartflow's revenue and profit?

- **Record Growth**: Q4 2025 revenue up 40% YoY to $49.1 million, with 53% global case growth and 80% non-GAAP gross margin.
- **Plaque Momentum**: 2026 plaque revenue guidance of $15-17 million, with 1,000+ accounts targeted by year-end. Autonomous Processing to drive 85%+ gross margin by mid-term.
- **Innovation Pipeline**: PCI Navigator launch in April 2026, with potential to expand FFRct utilization among interventional cardiologists.
- **Clinical Evidence**: 95% IVUS agreement for Plaque Analysis; 1-year DECIDE registry outcomes to be reported mid-2026.
- **Competitive Advantage**: Largest proprietary CT database (160M+ images), FDA clearance, and 600+ peer-reviewed publications.

**【CEO Summary Section】**
- **Record Q4 2025 Performance**: Total revenue of $49.1 million (+40% YoY), driven by 53% global case growth and 80% non-GAAP gross margin (up 470bps YoY). Full-year 2026 revenue guidance: $218-222 million (+24%-26% YoY), with plaque revenue targeting $15-17 million.
- **Strategic Pillars**: 
  1. **Commercial Adoption**: 340 new FFRct accounts added in 2025 (total 1,465), 489 Plaque accounts (80%+ utilization ramp in first year). 
  2. **Innovation Pipeline**: PCI Navigator launch pulled forward to April 2026, enabling AI-driven pre-procedural planning. Autonomous Processing initiative to reduce human oversight by 50% by 2027. 
  3. **Clinical Leadership**: 15,000-patient real-world Plaque registry at Mass General shows 95% IVUS agreement; 13,000-patient DECIDE registry 1-year outcomes to be reported mid-2026.
- **Market Expansion**: High-risk asymptomatic population targeted ($6B U.S. opportunity), with 3 RCTs planned for 2026.

**【CFO Financial Commentary】**
- **Q4 2025 Results**: 
  - Revenue: $49.1 million (+40% YoY)
  - Non-GAAP net loss: $9.8 million (-47% YoY)
  - Cash: $280.2 million
- **2026 Guidance**: 
  - Revenue: $218-222 million (+24%-26% YoY)
  - Gross margin: 80%-81% (vs. 75% in 2025)
  - Midterm gross margin target: 85% (up from 80%)
- **Key Drivers**: Volume leverage (+300-400bps YoY), AI efficiencies, and plaque revenue contribution (~$15-17 million in 2H26).

**【Q&A Highlights】**
- **Plaque Confidence**: Q1 2026 activations ahead of expectations; 1,000+ accounts by end-2026. Early volume trends indicate 2H26 ramp.
- **Competitive Moat**: 160M+ annotated CT images (largest proprietary database), 600+ peer-reviewed publications, and FDA-cleared medical device status.
- **PCI Navigator**: No incremental financial impact in 2026, but potential to drive FFRct utilization through interventional cardiologist adoption.
- **FFRCT Resilience**: 340 new accounts in 2025 (30%+ YoY growth), with steady-state utilization at ~30% of CCTA volume.


Heartflow Inc (HTFL) Q4 2025 Earnings Call Transcript

- **Revenue Surge**: Q3 2025 revenue up 41% YoY to $46.3M, with 48% case growth. Full-year guidance of $173M-$173.5M reflects strong adoption. 
- **AI Platform Expansion**: 4 integrated AI tools now serve 500K+ patients; next-gen Plaque Analysis 21% more accurate. 
- **Plaque Adoption Catalysts**: CMS Category 1 code Jan 2026, 57% U.S. coverage (target 70%+). 
- **PCI Navigator Innovation**: Pre-procedure planning tool launched in 2026, aligning with interventional cardiology trends. 
- **Financial Strength**: $291M cash post-IPO; gross margin 76.8% with path to 80%+. 
- **Growth Drivers**: 10% annual expansion of 2,900 U.S. target accounts; 600+ clinical studies validate AI platform. 


**【CEO Summary Section】**
- **Revenue Growth**: Q3 2025 revenue of $46.3 million, up 41% YoY, driven by 48% YoY growth in global revenue cases. Full-year 2025 guidance set at $173-$173.5 million (37.5%-38% growth). 
- **Platform Adoption**: 500,000+ patients served; 4 integrated AI products (Roadmap Analysis, Plaque Analysis, FFRCT, PCI Navigator) spanning CAD continuum. 
- **Strategic Pillars**: 
  1. **Commercial Expansion**: 2,900 U.S. target accounts; installed base growing 10% annually. 
  2. **Innovation Pipeline**: FDA-cleared next-gen Plaque Analysis (21% improvement), PCI Navigator launch in 2026. 
  3. **Clinical Leadership**: 600+ peer-reviewed studies, 110M+ annotated images. 
- **Plaque Analysis Milestones**: CMS Category 1 CPT code effective Jan 2026, 57% U.S. coverage (target 70%+ for adoption). 

**【CFO Financial Commentary】**
- **Financial Performance**: 
  - GAAP net loss: $50.9M; Non-GAAP net loss: $13.2M (vs. $16.2M YoY). 
  - Gross margin: 76.8% (vs. 75.9% YoY), driven by volume leverage. 
  - Operating expenses: $46.6M (101% of revenue vs. 114% YoY). 
- **Balance Sheet**: $291.2M cash post-IPO, zero debt. 
- **Guidance**: 80%+ gross margin achievable; cash flow breakeven in 3 years. 

**【Q&A Highlights】**
- **Plaque Adoption Timeline**: Material impact expected late 2026 (70%+ coverage needed). 
- **Navigator Impact**: Strengthens interventional cardiology engagement, aligns with TAVR-style pre-procedure planning. 
- **Sales Force Expansion**: TAM team doubling by end-2025; pharma-style market development vs. transactional sales. 
- **Clinical Data Momentum**: DECIDE registry shows 50%+ management changes; FISH & CHIPS study demonstrates plaque staging predictive power. 
- **Capital Allocation**: IPO proceeds ($332M net) funding R&D, commercial expansion, and clinical trials. 


Actual	-0.27	-0.12
Forecast	-0.2424	-0.1691
Surprise	-11.39%	+29.04%

Actual	46.28M	49.13M
Forecast	42.03M	46.58M
Surprise	+10.10%	+5.48%

HTFL

HTFL fundamentals

HTFL Q4 2025 Earnings

Earnings Call

You can ask Aime

HTFL

HTFL fundamentals

HTFL Q4 2025 Earnings

Earnings Call

HTFL Earnings Call Summary for Q4/20254:30 PM on Mar 18, 2026

HTFL Earnings Call Summary for Q3/20254:30 PM on Nov 12, 2025

You can ask Aime